Advanced data analytics
We select optimal historical clinical data for your
synthetic control arm using real world advanced analytics (RWA) solutions and core principles from epidemiology.
The increase in single arm trials in oncology and rare diseases has created challenges when it comes to comparing treatments. In response, the use of synthetic and external control arms has grown dramatically, enabled by improved access to data including statistical toolkits from many research fields. But are they the answer and what benefits do they bring?
Synthetic and external control arms allow you to augment single arm clinical trial data without battling the ethical and numerical enrolment challenges of a placebo- controlled randomized control trial. They could help deliver the results you need with as few as 25 patients, with clear benefits for your trial design and budget:
At Cytel we have 30 years’ experience of taking drug therapies from conception to commercialisation. We are experts at data sourcing, matching and processing to optimise synthetic control design and provide the valuable insights you need for success. Today we are one of the few companies with regulatory success in getting such applications approved in the market.
We select optimal historical clinical data for your
synthetic control arm using real world advanced analytics (RWA) solutions and core principles from epidemiology.
Our highly-skilled statisticians and data scientists employ advanced methods including Bayesian dynamic borrowing, propensity scoring, and quantitative bias assessment, to ensure historical data rigorously augments your trial.
Our forecasting engines identify what proportion of
your comparator arm should utilize historical data, helping you to optimize allocation of patients and avoid experiments on patients for marginal increases in scientific rigour.
Join four leading experts in the field as they help separate the myths about synthetic control from the reality.
Fill in the form below to get in touch